Merck: $7 billion reasons to hate Ivermectin
Oh look. We’re going to FINALLY get an outpatient treatment for COVID19!
Its only $700 per course!
We just have to wait a little bit longer. And – what are those side effects again? Any data on that?
Well don’t you worry your pretty little head about such things. NIH, WHO, and CDC have your back.
And since MOLNUPIRAVIR will be your only option for outpatient treatment in “The West”, you really won’t have a choice.
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for molnupiravir (MK-4482). Molnupiravir is currently being evaluated in a Phase 3 clinical trial, the MOVe-OUT study, for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics.
“Merck is pleased to collaborate with the U.S. government on this new agreement that will provide Americans with COVID-19 access to molnupiravir – an investigational oral therapy being studied for outpatient use early in the course of disease – if it is authorized or approved,” said Rob Davis, president, Merck. “In addition to this agreement with the U.S. government, we are actively engaged in numerous efforts to make molnupiravir available globally to fulfill Merck’s commitment to widespread access.”
Through the agreement, if molnupiravir receives Emergency Use Authorization (EUA) or approval by the U.S. Food and Drug Administration (FDA), Merck will receive approximately $1.2 billion to supply approximately 1.7 million courses of molnupiravir to the United States government. Merck has been investing at risk to support development and scale-up production of molnupiravir and expects to have more than 10 million courses of therapy available by the end of 2021.
Merck also plans to submit applications for emergency use or approval to regulatory bodies outside of the U.S. and is currently in discussions with other countries interested in advance purchase agreements for molnupiravir. Merck is committed to providing timely access to molnupiravir globally and intends to implement a tiered pricing approach based on World Bank data that recognizes countries’ relative ability to finance their public health response to the pandemic.
Note: the $7 billion in projected income is only for 2021. Paid for by You and Me, and by the deaths of all those who were unable to get Ivermectin between late last summer and today.
There really aren’t very many of them. Notice there were just a handful of … “people” on the Fauci GOF Coverup Email chain. Last time I checked, there are a whole lot of us. That’s why they installed the razor wire.
We could change this in seconds if we could just unite.
I will bet you anything that it is basically Ivermectin with an added molecule or two, so they can patent it and profit.
Dave, You have the thread title wrong. It should be “$7 billion reasons to hate Merck” not Ivermectin. This is just the latest volley. When will the people wise up and realize it is a big club that excludes them from being members? The goal isn’t to keep us healthier. It is to keep us healthy enough to extract as much as possible from us.
We’re on our own here, folks. – Grover
One minor detail… Probably nothing… But it may be mutagenic.
“In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties. A previous company, Pharmasset, that had investigated the drug’s active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals”
Animal studies? We don’t need no stinkin’ animal studies! This will be approved EUA! Just take it. It will be the only outpatient therapeutic allowed by the FDA in the USA.
This is a dangerous trend for Big Pharma. Looking for drugs that could make vaccines for viral disease obsolete.
Would Merck be doing this (to the vaccine industry) if there weren’t so many vaccine alternatives like IVM already raising their hands? Kind of a If You Can’t Beat Them, Then Join Them?
We told you for years there were no viable alternatives to Magic Vaccines. We have known that for a long time, but unfortunately now you also know. No matter, we have a solution. Bury the world in expensive Big Pharma anti-virals. We’ll make that vaccine money back somehow. And don’t worry, we’ll make sure there is a need for these products.
From one of the Wikipedia citations. And within this article there is a link to information about the funding of an HCQ/Pepcid trial.
The Bright allegation addressed by Benford’s email centers on a so far unsuccessful effort by Florida-based Ridgeback Biotherapeutics to win new federal funding to develop EIDD-2801, a version of a 4-decade-old antiviral drug, into a treatment for COVID-19. Although the drug has shown potential against the coronavirus that causes the disease, Bright had opposed providing an immediate large funding boost. He argued the drug had already received substantial government support, and some earlier studies suggested EIDD-2801 could cause harmful genetic mutations. In his complaint, Bright suggests Kadlec attempted to help Ridgeback sidestep a government contracting process that is supposed to be guided by science. In one email to BARDA, a Ridgeback executive wrote that Kadlec was “personally” pushing the company “to move fast, but we can’t without this authorization” for funding.
What a mess! And it sure doesn’t feel like anyone is interested in solving the problem.
Fox & Friends just scooped HCQ. Speculated with Tucker Carlsoon that hundreds of thousands of lives could have been saved were it not for Fauci and Big Pharma. Will they ever unravel this thing completely? Good one, Dave, thanks, but it won’t be surprising if this ‘new product’ is not as good as the ‘original’.
Yep, their treatments need to be just effective enough to justify a ridiculous price tag, but not effective enough to end or reduce the impact of the pandemic. Got to keep that cash cow alive and kicking.
They should have just stabbed us with a rusty shiv & named it ‘ivermectine’ or ‘ivermectous’. Better yet, ‘ivermecto’… sounds more like something from Idiocracy, which was meant to be a fictional movie, not a roadmap to the future.
Merck’s wonder drug, molnupiravir FAILED in the hospital setting and Merck abandoned that aspect of the clinical trial. Like remdesivir, it is a failure on hospitalized patients, no surprise because the virus stopped replications by the time patients make it to the hospital. Hey Merck, why don’t you do a head to head clinical trial comparing your wonder drug versus ivermectin for prevention of Covid and treatment of Covid at all stages. Let’s see how you do.
Such a sleaze bag business!